SCHEMBL5135950

SCHEMBL5135950

CCCCN(Cc1ccc(C(=O)OC)cc1)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 1/20 0.42
LPAR5 Q9H1C0 1/20 0.42
C5AR1 P21730 1/20 0.41
DRD2 P14416 1/20 0.41
TBXA2R P21731 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
AGTR1 P30556 2/20 0.40
HDAC1 Q13547 1/20 0.40
TLR7 Q9NYK1 3/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
PPARG P37231 1/20 0.38
PPARA Q07869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137376 0.94 C5AR1 (0.42) LPAR1LPAR5C5AR1DRD2TBXA2R
SCHEMBL5074064 0.91 LTA4H (0.45) LPAR1LPAR5C5AR1AGTR1HDAC1
SCHEMBL5135893 0.90 TLR7 (0.49) C5AR1TLR7
SCHEMBL5135490 0.90 SIRT2 (0.43) C5AR1DRD2TBXA2RL3MBTL1AGTR1
SCHEMBL650270 0.90 C5AR1 (0.43) C5AR1AGTR1HDAC1KDM4EALDH1A1
SCHEMBL648135 0.90 CRHR1 (0.44) LPAR1LPAR5DRD2TBXA2RL3MBTL1
SCHEMBL5137860 0.89 C5AR1 (0.41) C5AR1AGTR1HDAC1TLR7KDM4E
SCHEMBL4766957 0.89 C5AR1 (0.42) C5AR1AGTR1HDAC1TLR7PPARG
SCHEMBL5135677 0.88 C5AR1 (0.42) C5AR1HDAC1
SCHEMBL5135455 0.88 TLR7 (0.40) C5AR1HDAC1TLR7MGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed